In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.
Garenoxacin (BMS 284756) was active against 105 of 108 (97%) recent clinical Gardnerella vaginalis isolates at < or =2 micro g/ml by using the reference agar dilution method for anaerobes. Twenty-eight percent of isolates (31 of 108) were resistant to metronidazole, and 44% were resistant to doxycycline. All were susceptible to clindamycin and ampicillin-sulbactam.
Goldstein
Ellie J C
EJ
R. M. Alden Research Laboratory, Santa Monica-University of California Los Angeles Medical Center, 90404, USA. EJCGMD@aol.com
Citron
Diane M
DM
Merriam
C Vreni
CV
Warren
Yumi A
YA
Tyrrell
Kerin L
KL
Fernandez
Helen T
HT
D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D006194:Gardnerella vaginalis / Q000187:drug effects*; D007211:Indoles / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*
D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; C419689:garenoxacin